Which has better earnings and valuation, CTNM or PLYX?

Polaryx Therapeutics has lower revenue, but higher earnings than Contineum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Contineum Therapeutics $50M 8.88 -$59.98M -$1.95 N/A Polaryx Therapeutics N/A N/A N/A N/A N/A

Is CTNM or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -27.09% -25.64% Polaryx Therapeutics N/A N/A N/A

Which has higher valuation & earnings, IMMX or PLYX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A Polaryx Therapeutics N/A N/A N/A N/A N/A

Is IMMX or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Polaryx Therapeutics N/A N/A N/A

Which has preferable earnings and valuation, STRO or PLYX?

Polaryx Therapeutics has lower revenue, but higher earnings than Sutro Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sutro Biopharma $102.48M 4.66 -$191.09M -$11.04 N/A Polaryx Therapeutics N/A N/A N/A N/A N/A

Is STRO or PLYX more profitable?

Polaryx Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Company Net Margins Return on Equity Return on Assets Sutro Biopharma -154.21% N/A -69.20% Polaryx Therapeutics N/A N/A N/A

Which has higher earnings & valuation, PLYX or PRTA?

Polaryx Therapeutics has higher earnings, but lower revenue than Prothena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A N/A N/A Prothena $9.68M 44.62 -$244.09M -$2.82 N/A

Which has stronger valuation and earnings, PLYX or EOLS?

Polaryx Therapeutics has higher earnings, but lower revenue than Evolus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A N/A N/A Evolus $297.18M 1.49 -$51.64M -$0.67 N/A

Is PLYX or EOLS more profitable?

Polaryx Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Evolus -14.39% N/A -19.03%

Polaryx Therapeutics (PLYX) Competitors

$2.37 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.37 0.00 (-0.21%)

As of 06/12/2026 07:53 PM Eastern

Compare

PLYX vs. CTNM, IMMX, STRO, PRTA, and EOLS

Should you buy Polaryx Therapeutics stock or one of its competitors? MarketBeat compares Polaryx Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Polaryx Therapeutics include Contineum Therapeutics (CTNM), Immix Biopharma (IMMX), Sutro Biopharma (STRO), Prothena (PRTA), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry.

How does Polaryx Therapeutics compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Polaryx Therapeutics' return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 1 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.89 beat Polaryx Therapeutics' score of 0.44 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Contineum Therapeutics	Very Positive
Polaryx Therapeutics	Neutral

Polaryx Therapeutics has lower revenue, but higher earnings than Contineum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	8.88	-$59.98M	-$1.95	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Contineum Therapeutics currently has a consensus target price of $20.00, suggesting a potential upside of 68.35%. Polaryx Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 321.94%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Contineum Therapeutics and Polaryx Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Polaryx Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Immix Biopharma and Immix Biopharma both had 2 articles in the media. Immix Biopharma's average media sentiment score of 1.87 beat Polaryx Therapeutics' score of 0.44 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Immix Biopharma	Very Positive
Polaryx Therapeutics	Neutral

Immix Biopharma presently has a consensus target price of $19.50, indicating a potential upside of 130.77%. Polaryx Therapeutics has a consensus target price of $10.00, indicating a potential upside of 321.94%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.3% of Immix Biopharma shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Immix Biopharma beats Polaryx Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Sutro Biopharma currently has a consensus price target of $49.20, suggesting a potential upside of 70.83%. Polaryx Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 321.94%. Given Polaryx Therapeutics' higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Polaryx Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Sutro Biopharma had 3 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 5 mentions for Sutro Biopharma and 2 mentions for Polaryx Therapeutics. Sutro Biopharma's average media sentiment score of 0.97 beat Polaryx Therapeutics' score of 0.44 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sutro Biopharma	Positive
Polaryx Therapeutics	Neutral

Polaryx Therapeutics has lower revenue, but higher earnings than Sutro Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	4.66	-$191.09M	-$11.04	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

97.0% of Sutro Biopharma shares are owned by institutional investors. 5.9% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Sutro Biopharma beats Polaryx Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Prothena?

Polaryx Therapeutics (NASDAQ:PLYX) and Prothena (NASDAQ:PRTA) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Polaryx Therapeutics has higher earnings, but lower revenue than Prothena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Prothena	$9.68M	44.62	-$244.09M	-$2.82	N/A

Polaryx Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 321.94%. Prothena has a consensus target price of $23.75, indicating a potential upside of 187.88%. Given Polaryx Therapeutics' higher possible upside, equities analysts plainly believe Polaryx Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Polaryx Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Polaryx Therapeutics' return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Prothena	-260.92%	-43.44%	-36.87%

In the previous week, Prothena had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 3 mentions for Prothena and 2 mentions for Polaryx Therapeutics. Prothena's average media sentiment score of 1.45 beat Polaryx Therapeutics' score of 0.44 indicating that Prothena is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Prothena	Positive

97.1% of Prothena shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Prothena beats Polaryx Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Evolus?

Polaryx Therapeutics (NASDAQ:PLYX) and Evolus (NASDAQ:EOLS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 321.94%. Evolus has a consensus target price of $16.00, indicating a potential upside of 137.74%. Given Polaryx Therapeutics' higher probable upside, research analysts clearly believe Polaryx Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

90.7% of Evolus shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Evolus had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 3 mentions for Evolus and 2 mentions for Polaryx Therapeutics. Evolus' average media sentiment score of 0.94 beat Polaryx Therapeutics' score of 0.44 indicating that Evolus is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Evolus	Positive

Polaryx Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Evolus	-14.39%	N/A	-19.03%

Polaryx Therapeutics has higher earnings, but lower revenue than Evolus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Evolus	$297.18M	1.49	-$51.64M	-$0.67	N/A

Summary

Evolus beats Polaryx Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Polaryx Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLYX vs. The Competition

Export

Metric	Polaryx Therapeutics	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$111.46M	$2.95B	$4.29B	$12.05B
Dividend Yield	N/A	15.26%	10.25%	5.66%
P/E Ratio	N/A	13.63	22.29	24.42
Price / Sales	N/A	3,048.38	159.54	118.72
Price / Cash	N/A	26.81	40.19	37.92
Price / Book	N/A	4.80	26.92	6.82
Net Income	N/A	-$39.47M	$116.61M	$337.56M
7 Day Performance	-3.66%	0.47%	0.25%	1.16%
1 Month Performance	-11.24%	0.64%	0.25%	3.16%
1 Year Performance	N/A	16.43%	14.25%	30.60%

Polaryx Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLYX Polaryx Therapeutics	4.067 of 5 stars	$2.37 flat	$10.00 +321.9%	N/A	$111.46M	N/A	N/A	11	Short Interest Increase
CTNM Contineum Therapeutics	2.4993 of 5 stars	$11.88 +0.2%	$20.00 +68.4%	+168.2%	$443.40M	$50M	N/A	31
IMMX Immix Biopharma	3.4711 of 5 stars	$8.45 +4.3%	$19.50 +130.8%	+259.6%	$440.73M	N/A	N/A	9	Positive News
STRO Sutro Biopharma	4.3787 of 5 stars	$28.80 +8.8%	$49.20 +70.8%	+260.4%	$438.79M	$102.48M	N/A	240	News Coverage Analyst Downgrade Short Interest Decrease Gap Down
PRTA Prothena	3.0377 of 5 stars	$8.25 -0.1%	$23.75 +187.9%	+62.4%	$432.44M	$9.68M	N/A	130	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLYX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. CTNM, IMMX, STRO, PRTA, and EOLS

How does Polaryx Therapeutics compare to Contineum Therapeutics?

Summary

How does Polaryx Therapeutics compare to Immix Biopharma?

Summary

How does Polaryx Therapeutics compare to Sutro Biopharma?

Summary

How does Polaryx Therapeutics compare to Prothena?

Summary

How does Polaryx Therapeutics compare to Evolus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. CTNM, IMMX, STRO, PRTA, and EOLS

How does Polaryx Therapeutics compare to Contineum Therapeutics?

Is CTNM or PLYX more profitable?

Does the media favor CTNM or PLYX?

Which has better earnings and valuation, CTNM or PLYX?

Do analysts rate CTNM or PLYX?

Summary

How does Polaryx Therapeutics compare to Immix Biopharma?

Is IMMX or PLYX more profitable?

Does the media prefer IMMX or PLYX?

Do analysts recommend IMMX or PLYX?

Do insiders and institutionals have more ownership in IMMX or PLYX?

Which has higher valuation & earnings, IMMX or PLYX?

Summary

How does Polaryx Therapeutics compare to Sutro Biopharma?

Do analysts recommend STRO or PLYX?

Is STRO or PLYX more profitable?

Does the media prefer STRO or PLYX?

Which has preferable earnings and valuation, STRO or PLYX?

Do institutionals & insiders have more ownership in STRO or PLYX?

Summary

How does Polaryx Therapeutics compare to Prothena?

Which has higher earnings & valuation, PLYX or PRTA?

Do analysts prefer PLYX or PRTA?

Is PLYX or PRTA more profitable?

Does the media favor PLYX or PRTA?

Do institutionals and insiders believe in PLYX or PRTA?

Summary

How does Polaryx Therapeutics compare to Evolus?

Do analysts rate PLYX or EOLS?

Do insiders & institutionals believe in PLYX or EOLS?

Does the media prefer PLYX or EOLS?

Is PLYX or EOLS more profitable?

Which has stronger valuation and earnings, PLYX or EOLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools